Epstein Secrets

at current levels. The fundamental bull case for Health rests on the strong pipeline of new products for

h (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS): Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Investment Industry Regul

at current levels. The fundamental bull case for Health rests on the strong pipeline of new products for

h (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Investment Industry Regul

-12 1% 78 3.0% -13 % 33 -0.4% 6 68% -0./% SXDP (Health) 3.0% -08% 1% 8.7% 0.9% 9 2% 115 2.5% -12 3% 40

n Branch (ARBN his report in Austra by Merrill regulated itutional ia only to ports ed, in any Limited in port. Singapore recipients of ) and/or Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection 28 Global Equity Volatility Insights | 20 June 2017 BankofAmerica Merrill Lynch HOUSE_OV

ncrease penetration of higher margin offerings 48 Health: Not Tremendously Prescriptive 51 Vision 2030 a s

fic advice on securities. Singapore recipients of this research report should contact Merrill Lynch International Bank Limited (Merchant Bank) and/or Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this research report. General Investment Related Disclosures: Taiwan Readers: Neither

ervices 1,720 Tax credit for orphan drug research Health 100 Exclusion & deferral of policyholder income e

d not futures contracts). Singapore recipients of this research report should contact Merrill Lynch International Bank Limited (Merchant Bank) and/or Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this research report. General Investment Related Disclosures: Taiwan Readers: Neither